A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.

Paul G CornMiao ZhangGraciela M Nogueras-GonzalezLianchun XiaoAmado J ZuritaSumit K SubudhiShi-Ming TuAna M AparicioCristian CoarfaKimal RajapaksheShixia HuangNora M NavoneSue-Hwa LinGuocan WangSumankalai RamachandranMark A TitusTheocharis PanaretakisGary E GallickEleni EfstathiouPatricia TroncosoChristopher Logothetis

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Cabozantinib plus ADT has promising clinical activity in HNMPCa. CAF profiles and tissue markers suggest candidate prognostic and predictive markers of cabozantinib benefit and provide insights for rational therapy combinations.

Keyphrases

phase ii study
prostate cancer
metastatic renal cell carcinoma
open label
locally advanced
squamous cell carcinoma
radical prostatectomy
small cell lung cancer
stem cells
clinical trial
rectal cancer
placebo controlled
radiofrequency ablation
cell therapy
atrial fibrillation
study protocol